CN104491726A - Traditional Chinese medicine composition for treating prostatic hyperplasia and preparation method of traditional Chinese medicine composition - Google Patents
Traditional Chinese medicine composition for treating prostatic hyperplasia and preparation method of traditional Chinese medicine composition Download PDFInfo
- Publication number
- CN104491726A CN104491726A CN201410811272.XA CN201410811272A CN104491726A CN 104491726 A CN104491726 A CN 104491726A CN 201410811272 A CN201410811272 A CN 201410811272A CN 104491726 A CN104491726 A CN 104491726A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicines, relates to a traditional Chinese medicine composition and a preparation method thereof as well as in particular relates to a traditional Chinese medicine composition for treating prostatic hyperplasia and a preparation method of the traditional Chinese medicine composition. Aiming at the technical deficiencies of the traditional chemical treatment medicament of the prostatic hyperplasia of large hepatotoxicity and poor curative effect, the invention provides the traditional Chinese medicine composition for treating or preventing the prostatic hyperplasia. The traditional Chinese medicine composition is prepared from the following medicinal raw materials in parts by weight: 10-15 parts of radix puerariae, 10-20 parts of galanga resurrectionlily rhizome, 5-20 parts of corydalis tuber, 5-15 parts of fritillaria, 5-10 parts of cortex moutan, 5-15 parts of radix curcumae, 5-15 parts of Chinese arborvitae, 1-10 parts of frankincense, 5-15 parts of radix rubiae, 9-15 parts of common anemarrhena rhizome, 9-15 parts of Chinese elder herb, 5-15 parts of sophora flavescens ait, 0.2-9 parts of virgate wormwood herb, 5.5-15 parts of sappan wood, 6-9 parts of gorgon fruit and 10-15 parts of pachyma cocos. The traditional Chinese medicine composition has good therapeutic effect of treating or preventing the prostatic hyperplasia, is low in side effect of drug and has remarkable clinic popularization value.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of Chinese medicine composition for the treatment of prostatic hyperplasia and preparation method thereof.
Background technology
Hyperplasia of prostate (BPH), is once called as prostate hyperplasia, is one of older men common disease, and be prostatic a kind of benign lesion, its pathogenic factor is relevant with estrogenic dysequilibrium with androgen in human body.Pathological changes originates from the glandular tissue of middle period under Posterior urethral mucosa or lateral lobe, connective tissue and smooth muscle tissue, form Combination spherical shape tuberosity, be obviously with two lateral lobes and middle lobe hyperplasia, charge in bladder or urethra, compressing bladder neck or urethra, cause lower urinary tract obstruction.Pathological changes can cause hydronephrosis and renal function injury for a long time.Also can concurrent calculus, infection, tumor etc.
The pathogenesis of prostatic hyperplasia, is generally acknowledged with the endocrine theory of gonadal hormone dysequilibrium at present.Sex hormone level is disorderly closely related with the generation of hyperplasia of prostate; Give a certain amount of exogenous androgen, sex hormone level in animal body can be caused disorderly, make prostate generation hypertrophy, can prostatic hyperplasia model be caused.Prostatic hyperplasia the most intuitively pathological manifestations is that prostate volume increases, weight increases and benign prostatic hyperplasia under light microscopic, and prostate index is one of the most objective index of reflection prostatic hyperplasia degree.The generation of prostatic hyperplasia is based on glandular hyperplasia, and main manifestations is lumen of gland expansion, volume increases, glandular epithelium increased number.
A large amount of clinical experiences proves, application gynotermone treatment prostate hyperplasia, can obtain good effect.Domestic gate of a village great waves in morning are 80% have good effect in the experience of nineteen fifty-nine report Benovocylin treatment primary disease, Wang Ligeng is 75% in the effect of 62 annual report gynotermone treatment primary disease, there is Topchan to treat prostate hyperplasia 244 example 76.2% in nineteen fifty-one report Synestrol abroad and obtain good effect, thereafter treat again 103 examples, 82% is respond well.The consumption of Synestrol is 40 ~ 60 milligrams of intramuscular injection, within two months, is a curative effect.Ende, at the quiet note treatment of 17 routine prostate hyperplasia complicated with urine retention patient Premerin after date for the moment, is all fully recovered, through not having recurrence with examining more than 1 year 16 examples.Current application Benovocylin treatment prostate hyperplasia has been the method extensively adopted, but directly uses hormone easily can cause larger treatment pressure to the physiology of patient and spiritual aspect.α beta blocker, 5α-reductase inhibitor are also usually used in treatment or the prevention of prostatic hyperplasia in addition, but side effect is comparatively large, and clinical in easily there is drug resistance.In a word, the Western medicine for the treatment of prostatic hyperplasia is a lot, but most drug therapeutic effect is poor, and treats into the shortcomings such as high, side effect is large in addition, even affects patient health time serious.And Chinese medicine prostatic hyperplasia curative effect is reliable, toxic and side effects is little, has broad prospects.But mostly adopt Fructus Xanthii Flos Magnoliae etc., feature has certain drug toxicity, can not long-term taking, and also long-term effect is undesirable, and large for nasal drop local irritation, curative effect is of short duration.Namely the object of the invention is to provide a kind of effect comprehensively, the Chinese medicine composition of the treatment prostatic hyperplasia that clinical effectiveness is good.
Summary of the invention
Large in order to overcome existing prostatic hyperplasia chemotherapeutic agent toxic and side effects, the prior art that Treatment of Benign Prostatic Hyperplasia effect is difficult to continue is not enough, the invention provides a kind of Chinese medicine composition for the treatment of prostatic hyperplasia, this Chinese medicine composition good effect, side effect is little, it obtains primarily of following raw material: Radix Puerariae 10-50 part, Rhizoma Kaempferiae 10-20 part, Rhizoma Corydalis 5-20 part, Bulbus Fritillariae Uninbracteatae 5-15 part, Cortex Moutan 5-10 part, Radix Curcumae 5-15 part, Cacumen Platycladi 5-15 part, Olibanum 1-10 part, Radix Rubiae 5-15 part, Rhizoma Anemarrhenae 9-15 part, Herba Sambuci Chiensis 9-15 part, Radix Sophorae Flavescentis 5-15 part, Herba Artemisiae Scopariae 0.2-9 part, Lignum Sappan 5.5-15 part, Semen Euryales 6-9 part, Poria 10-15 part.
Chinese medicine composition of the present invention with except long-pending numbness, dispersing wind and cold, wind-damp dispelling, bone and muscle strengthening are for main standard, has significant antiinflammatory, analgesia and activating blood circulation to dissipate blood stasis effect after Chinese medicine composition combination of the present invention on Chinese medicinal components is selected.The parts by weight of the present invention to above-mentioned all taste Chinese medicine carry out preferably, preferred condition be after drug matching uses medicine to the enhancing of Treatment of Benign Prostatic Hyperplasia effect.As a preferred embodiment of the present invention, Chinese medicine composition of the present invention obtains primarily of the raw material of following weight portion: Radix Puerariae 30 parts, Rhizoma Kaempferiae 15 parts, Rhizoma Corydalis 15 parts, Bulbus Fritillariae Uninbracteatae 10 parts, Cortex Moutan 8 parts, Radix Curcumae 10 parts, Cacumen Platycladi 10 parts, Olibanum 6 parts, 10 parts, Radix Rubiae, the Rhizoma Anemarrhenae 12 parts, Herba Sambuci Chiensis 12 parts, Radix Sophorae Flavescentis 10 parts, Herba Artemisiae Scopariae 5.5 parts, Lignum Sappan 10 parts, Semen Euryales 8 parts, 12 parts, Poria.
Preferably, Chinese medicine composition of the present invention also contains Radix Stephaniae Tetrandrae 7 parts further, Rhizoma Et Radix Notopterygii 5 parts, Rhizoma Alpiniae Officinarum 9 parts.
In order to express Chinese medicine composition of the present invention better, Chinese medicine composition of the present invention can be prepared into dosage form conventional clinically.Such as, the preparation such as powderous preparations, powder, pill, sublimed preparation, unguentum, granule, oral liquid, syrup, tablet, capsule.Preferably, Chinese medicine composition of the present invention conveniently preparation technology be prepared into powder, water preparation, tablet or capsule.
Present invention also offers a kind of preparation method of Chinese medicine composition described above, it mainly comprises following step: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, the alcoholic solution that volumetric concentration is 40% ~ 95% is added according to 4 ~ 9 times of coarse powder gross weight, reflux, extract, three times, return time is 2 ~ 5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
The present invention also asks to protect the purposes of above-mentioned Chinese medicine composition in preparation treatment prostatic hyperplasia agents.Pharmaceutical composition of the present invention before the treatment row gland hypertrophy time, the heavy and prostate index of mouse prostate model of hyperplasia prostate can be reduced, and the hormonal readiness of patient can be regulated.The embodiment of the present invention 19 shows, invention Chinese medicine composition group significantly can reduce mouse prostate model of hyperplasia prostate and weigh and prostate index, have the difference of significance with model group, wherein, dosage group and high dose group are significantly better than LONGBISHU group to the therapeutical effect of prostatic hyperplasia.Meanwhile, compared with model group, LONGBISHU group, Chinese medicine composition group of the present invention all can significantly reduce testosterone levels in model mice serum, and wherein in Chinese medicine composition senior middle school of the present invention dosage group reduction model mice serum, testosterone levels aspect is better than Longbishu Jiaonang. group.In addition, Chinese medicine composition group of the present invention can obviously raise mice serum estradiol level.
In a word, pharmaceutical composition of the present invention is row gland hypertrophy aspect before the treatment, compared with prior art has following advantage:
1) compared with positive control drug Longbishu Jiaonang. group, pharmaceutical composition Chinese medicine composition of the present invention can not only reduce mouse prostate model of hyperplasia prostate and weigh and prostate index, and regulate the hormonal readiness of patient, this shows that the present composition has significant synergism in Treatment of Benign Prostatic Hyperplasia, significantly can not only improve the symptom of prostatic hyperplasia, the development of prostatic hyperplasia can also be delayed, thus the effect for the treatment of both the principal and secondary aspects of a disease is played for prostatic hyperplasia.
2) compared with the chemotherapeutic agent of Current therapeutic prostatic hyperplasia, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, untoward reaction and side effect significantly reduce, particularly it does not produce any destruction for liver and intestinal mucosa, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, significantly improves the compliance of Patients with Prostatic Hyperplasia, and improves the quality of life of patient.
3) existing chemotherapeutic agent prostatic hyperplasia initial therapy effect still can, but all occur obvious drug resistance problem along with the prolongation for the treatment of time, its therapeutic effect for prostatic hyperplasia declines.Containing multi-medicament component in Chinese medicine composition of the present invention, action target spot is numerous, efficiently solves the Commpensation And Adaptation of Treatment of Benign Prostatic Hyperplasia medicine, and it does not decline because treatment time extends to the therapeutic effect of prostatic hyperplasia.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, the change carried out the present invention, combination or replacement, be apparent for a person skilled in the art, and be included within the scope of the present invention.
Part I Chinese medicinal composition preparation of the present invention, preparation and using method thereof
Embodiment 1-6 Chinese medicine composition composition powders
Table 1 Chinese medicine composition composition powders of the present invention prescription
Embodiment 1 preparation method: get each medical material in compositions, conveniently technique grinds to form powdery, cross 100 mesh sieves, little fire drying is for subsequent use, obtains powder.During use, directly take after mixing it with water with after water dissolution.Embodiment 2-6 preparation method is with embodiment 1.
Embodiment 7-12 Chinese medicine composition water preparation
Table 2 Chinese medicine composition water preparation of the present invention prescription
Embodiment 7 preparation method: get each medical material in prescription, conveniently decocting for Chinese herbal medicine technological operation, filtering medicinal residues and get final product.When this water preparation (or claiming decoction) is for Treatment of Benign Prostatic Hyperplasia, daily 2-3 time.Embodiment 8-12 preparation method and using method are with embodiment 7.
Embodiment 13-18 Chinese medicine composition tablet/capsule of the present invention
Table 3 Chinese medicine composition tablet of the present invention/capsule prescription
Embodiment 13 preparation technology: each traditional Chinese medicine powder getting recipe quantity is broken into coarse powder, adds according to 5 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 80%, reflux, extract, three times, the each 3h of return time, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; By Chinese medical concrete drying, pulverize and make dried cream powder, add customary adjuvant components utilising prior art and be prepared into tablet or capsule.
Embodiment 14-18 preparation technology is with embodiment 13.
Part II Chinese medicine composition pharmacodynamic study of the present invention
Embodiment 19 Chinese medicine composition of the present invention is on the impact of prostatic hyperplasia mouse model
Mice is divided into 6 groups at random, wherein 5 groups with Testosterone Propionate (being dissolved in Oleum Glycines) every day by the modeling of 5m g/kg subcutaneous injection, continuous 3 weeks.Modeling 5 groups gavages the Chinese medicine composition of the present invention (2g/kg, 1g/kg, 0.5g/kg) of large, medium and small dosage, Longbishu Jiaonang. (450m g/kg) or isopyknic normal saline respectively, every day 1 time, continuous 3 weeks, wherein Chinese medicine composition of the present invention prepared according to the formulation and technology described in embodiment 1.Another 1 group is blank.After last administration, (fasting 12h) 1h, weighs, and socket of the eye venous blood sampling is centrifugal, separation of serum.Survey testosterone (T), estradiol (E2) level in serum with putting method of exempting from, assay method presses the operation of test kit description.Then de-cervical vertebra puts to death mice, gets prostata tissue rapidly, weighs; And calculate prostate index (prostate index=prostate weight in wet base m g/ Mus body weight g).
Table 4 Chinese medicine composition of the present invention is on the impact of prostatic hyperplasia mouse model
Note: compare with normal control,
##p < 0.01; Compare with model group,
*p < 0.05,
*p < 0.01
As can be seen from Table 4, compared with blank group, the prostate of model group mice weighs and prostate index all significantly increases.Compared with model group, LONGBISHU group obviously can reduce mouse prostate model of hyperplasia prostate and weigh and prostate index; Chinese medicine composition group of the present invention significantly can reduce mouse prostate model of hyperplasia prostate and weigh and prostate index, has the difference of significance with model group, and wherein, dosage group and high dose group are significantly better than LONGBISHU group to the therapeutical effect of prostatic hyperplasia.
Table 5 Chinese medicine composition of the present invention is on the impact of prostatic hyperplasia mouse model hormonal readiness
Note: compare with normal control,
##p < 0.01; Compare with model group,
*p < 0.05,
*p < 0.01
As seen from Table 5, compared with blank group, in model group mice serum, testosterone levels significantly raises.Compared with model group, LONGBISHU group, Chinese medicine composition group of the present invention all can significantly reduce testosterone levels in model mice serum, and wherein in Chinese medicine composition senior middle school of the present invention dosage group reduction model mice serum, testosterone levels aspect is better than Longbishu Jiaonang. group.In addition, Chinese medicine composition group of the present invention can obviously raise mice serum estradiol level.
Claims (7)
1. treat a Chinese medicine composition for prostatic hyperplasia, it is characterized in that it obtains primarily of the raw material of following weight portion:
Radix Puerariae 10-50 part, Rhizoma Kaempferiae 10-20 part, Rhizoma Corydalis 5-20 part, Bulbus Fritillariae Uninbracteatae 5-15 part, Cortex Moutan 5-10 part, Radix Curcumae 5-15 part, Cacumen Platycladi 5-15 part, Olibanum 1-10 part, Radix Rubiae 5-15 part, Rhizoma Anemarrhenae 9-15 part, Herba Sambuci Chiensis 9-15 part, Radix Sophorae Flavescentis 5-15 part, Herba Artemisiae Scopariae 0.2-9 part, Lignum Sappan 5.5-15 part, Semen Euryales 6-9 part, Poria 10-15 part.
2. Chinese medicine composition as claimed in claim 2, is characterized in that it also containing, for example the raw material of lower weight portion: Herba Sambuci Chiensis 7 parts, Rhizoma Et Radix Notopterygii 5 parts and Rhizoma Alpiniae Officinarum 9 parts.
3. Chinese medicine composition as claimed in claim 1, is characterized in that it obtains primarily of the raw material of following weight portion:
Radix Puerariae 30 parts, Rhizoma Kaempferiae 15 parts, Rhizoma Corydalis 15 parts, Bulbus Fritillariae Uninbracteatae 10 parts, Cortex Moutan 8 parts, Radix Curcumae 10 parts, Cacumen Platycladi 10 parts, Olibanum 6 parts, 10 parts, Radix Rubiae, the Rhizoma Anemarrhenae 12 parts, Herba Sambuci Chiensis 12 parts, Radix Sophorae Flavescentis 10 parts, Herba Artemisiae Scopariae 5.5 parts, Lignum Sappan 10 parts, Semen Euryales 8 parts, 12 parts, Poria.
4. Chinese medicine composition as claimed in claim 2, is characterized in that it also containing, for example the raw material of lower weight portion: Radix Stephaniae Tetrandrae 7 parts, Rhizoma Et Radix Notopterygii 5 parts and Rhizoma Alpiniae Officinarum 9 parts.
5. the Chinese medicine composition as described in as arbitrary in claim 1-4, is characterized in that it is powder, water preparation, tablet or capsule.
6. prepare the method for Chinese medicine composition as claimed in claim 5 for one kind, it is characterized in that it comprises the following steps:: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, the alcoholic solution that volumetric concentration is 40% ~ 95% is added according to 4 ~ 9 times of coarse powder gross weight, reflux, extract, three times, return time is 2 ~ 5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying.
7. the Chinese medicine composition as described in as arbitrary in claim 1-4 is purposes in preparation treatment prostatic hyperplasia agents.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410811272.XA CN104491726A (en) | 2014-12-22 | 2014-12-22 | Traditional Chinese medicine composition for treating prostatic hyperplasia and preparation method of traditional Chinese medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410811272.XA CN104491726A (en) | 2014-12-22 | 2014-12-22 | Traditional Chinese medicine composition for treating prostatic hyperplasia and preparation method of traditional Chinese medicine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104491726A true CN104491726A (en) | 2015-04-08 |
Family
ID=52933240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410811272.XA Pending CN104491726A (en) | 2014-12-22 | 2014-12-22 | Traditional Chinese medicine composition for treating prostatic hyperplasia and preparation method of traditional Chinese medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104491726A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104815161A (en) * | 2015-04-27 | 2015-08-05 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating prostatic hyperplasia combined kidney stone and preparation method of traditional Chinese medicine composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1753682A (en) * | 2003-01-16 | 2006-03-29 | 利盛私人有限公司 | The herbal-composition that is used for prostatosis |
| CN102657840A (en) * | 2012-06-06 | 2012-09-12 | 韩源圣 | Stasis-removing and inflammation-diminishing traditional Chinese medicine composition, stasis-removing and inflammation-diminishing pills, stasis-removing and inflammation-diminishing plaster and preparation method thereof |
| CN103202967A (en) * | 2013-05-08 | 2013-07-17 | 葛晓云 | Medicine for treating prostatitis and preparation method thereof |
-
2014
- 2014-12-22 CN CN201410811272.XA patent/CN104491726A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1753682A (en) * | 2003-01-16 | 2006-03-29 | 利盛私人有限公司 | The herbal-composition that is used for prostatosis |
| CN102657840A (en) * | 2012-06-06 | 2012-09-12 | 韩源圣 | Stasis-removing and inflammation-diminishing traditional Chinese medicine composition, stasis-removing and inflammation-diminishing pills, stasis-removing and inflammation-diminishing plaster and preparation method thereof |
| CN103202967A (en) * | 2013-05-08 | 2013-07-17 | 葛晓云 | Medicine for treating prostatitis and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 刘春棋等: "葛根素对小鼠前列腺增生的作用研究", 《中药药理与临床》 * |
| 方诺等: "益气活血清热利湿方对大鼠前列腺增生模型碱性成纤维因子的影响", 《河北中医》 * |
| 陈恕民: "宣肺活血利水方治疗前列腺增生症43例", 《陕西中医》 * |
| 马治国等: "化瘀通癃汤治疗前列腺增生症38例", 《陕西中医》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104815161A (en) * | 2015-04-27 | 2015-08-05 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating prostatic hyperplasia combined kidney stone and preparation method of traditional Chinese medicine composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9744206B2 (en) | Pharmaceutical compositions for treating cancer of genital system and preparation method therefor | |
| US10653746B2 (en) | Medicament for use in treating gout | |
| CN103961559A (en) | Styptic powder with dendrobium officinale | |
| Zhuang et al. | Interaction between Chinese medicine and digoxin: Clinical and research update | |
| CN104971102B (en) | The pharmaceutical composition and its preparation method and application for treating diabetic nephropathy | |
| CN110368445B (en) | Traditional Chinese medicine composition for treating psoriasis as well as preparation method and application thereof | |
| CN101850094B (en) | Chinese medicinal adhesive plaster | |
| CN105434915A (en) | Pharmaceutical composition for treating urolithiasis for dogs and cats and preparation method of pharmaceutical composition | |
| CN101664533B (en) | Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method | |
| CN103405653B (en) | External preparation for treating gouty arthritis | |
| CN112755140B (en) | Pharmaceutical composition for treating gouty arthritis and preparation method and application thereof | |
| CN104491726A (en) | Traditional Chinese medicine composition for treating prostatic hyperplasia and preparation method of traditional Chinese medicine composition | |
| CN104548016A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hyperuricemia | |
| CN104258051A (en) | Traditional Chinese medicine composition for treating gouty arthritis, and preparation method thereof | |
| CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
| CN1292275A (en) | Chinese medicine preparation for curing postpartum disease of woman | |
| CN114558090B (en) | Medicine for treating benign prostatic hyperplasia | |
| CN115252731B (en) | Traditional Chinese medicine composition for treating eczema and preparation method and application thereof | |
| CN106902295B (en) | Toxicity-reducing and efficacy-enhancing traditional Chinese medicine tablet for treating gout with syndrome of wind-damp-heat | |
| CN104623050B (en) | A kind of medicament for the treatment of corticosteroid femur head necrosis | |
| CN104815161A (en) | Traditional Chinese medicine composition for treating prostatic hyperplasia combined kidney stone and preparation method of traditional Chinese medicine composition | |
| CN101757460A (en) | Traditional Chinese medicine preparation for treating gout | |
| CN1301727C (en) | Externally applied Chinese medicine preparation for treating skin disease and its preparation method | |
| CN105168484A (en) | Traditional Chinese medicine composition for treating female chronic urinary tract infection complicated with pelvic cavity pain | |
| CN105326899A (en) | Traditional Chinese medicine for treating leukoderma and preparation method for traditional Chinese medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150408 |